Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
Authors:
- Heinz WiendlHWHeinz Wiendl
- Frederik BarkhofFBFrederik Barkhof
- Xavier MontalbanXMXavier Montalban
- Anat AchironAAAnat Achiron
- Tobias DerfussTDTobias Derfuss
- Andrew ChanAndrew Chan
- Suzanne HodgkinsonSHSuzanne Hodgkinson
- Alexandre PratAPAlexandre Prat
- Letizia LeocaniLetizia Leocani
- Klaus SchmiererKSKlaus Schmierer
- Finn SellebjergFSFinn Sellebjerg
- Patrick VermerschPVPatrick Vermersch
Open Access
- 4 November 2025
- journal article
- Published by Taylor & Francis in Video Journal of Biomedicine
- Vol. 7 (1) , 1-5
Abstract
This animated video presents the MAGNIFY-MS study, which investigated immune changes following cladribine tablets treatment of relapsing MS.Keywords
Funding Information
- Merck KGaA
This publication has 9 references indexed in Scilit:
- Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective studyMultiple Sclerosis Journal, 2023
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidenceMultiple Sclerosis and Related Disorders, 2022
- Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation, 2022
- Long-term safety data from the cladribine tablets clinical development program in multiple sclerosisMultiple Sclerosis and Related Disorders, 2020
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2019
- Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markersTherapeutic Advances in Neurological Disorders, 2019
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- CladribineClinical Neuropharmacology, 2011
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010